Sarepta Therapeutics Inc (SRPT)

05:55 AM

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph

05:55 AM

05:54 AM

Sarepta's Aggressive Growth: 39 New Hires Receive Substantial Equity Package - Stock Titan

05:54 AM

04:09 AM

Top vaccine official’s ouster sends biotech stocks tumbling - The Boston Globe

04:09 AM

01:59 AM

Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com

01:59 AM

01:45 AM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire

01:45 AM

01:29 AM

Why Sarepta Therapeutics (SRPT) Stock Is Nosediving - Yahoo Finance

01:29 AM

11:31 AM

Moderna Stock Sinks After Top FDA Official Resigns; Sarepta Gets Hit, Too. - MSN

11:31 AM

11:01 AM

RBC Capital Downgrades Sarepta Therapeutics (BMV:SRPT) - Nasdaq

11:01 AM

10:54 AM

Sarepta downgraded at RBC Capital on gene therapy concerns (SRPT:NASDAQ) - Seeking Alpha

10:54 AM

10:47 AM

Fiery Resignation of Top FDA Official Sparks Biotech Stock Selloff - Barron's

10:47 AM

10:36 AM

Sarepta Craters After RBC’s 45% Price Target Cut - Wall Street Pit

10:36 AM

08:20 AM

Drugmakers tumble on reports FDA's top vaccine regulator set to leave - MarketScreener

08:20 AM

07:28 AM

A recent gene therapy death shines a light on AAV safety - PharmaVoice

07:28 AM

07:25 AM

Biotech stocks tumble on reports FDA's top vaccine regulator to leave - MarketScreener

07:25 AM

07:15 AM

RBC Downgrades Sarepta Therapeutics to Sector Perform From Outperform, Adjusts PT to $87 From $161 - MarketScreener

07:15 AM

Mar 30, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation - markets.businessinsider.com

Mar 30, 2025

Mar 30, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta - Bluefield Daily Telegraph

Mar 30, 2025

Mar 29, 2025

Is Sarepta Therapeutics (SRPT) the Best Mid Cap Biotech Stock to Buy? - Yahoo Finance

Mar 29, 2025

Mar 28, 2025

Why Sarepta Therapeutics Inc. (SRPT) Crashed On Tuesday? - MSN

Mar 28, 2025

Mar 28, 2025

Dravet Gene Therapy Tested in Mice, Sarepta’s Setback, and AstraZeneca Updates - Genetic Engineering & Biotechnology News

Mar 28, 2025

Mar 28, 2025

Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider

Mar 28, 2025

Mar 28, 2025

Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Mar 28, 2025

Mar 27, 2025

Safety Questions Loom in Duchenne as Dyne, Wave and Others Plan FDA Filings - BioSpace

Mar 27, 2025

Mar 26, 2025

Wave Aspires To Accelerated Approval In DMD With 48-Week Data - News & Insights

Mar 26, 2025

Mar 26, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Mar 26, 2025

Mar 26, 2025

Wave strengthens case for accelerated approval, with more positive Duchenne data - Endpoints News

Mar 26, 2025

Mar 25, 2025

Sarepta stock plunges to 52-week low, touches $73 By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

Sarepta stock plunges to 52-week low, touches $73 - Investing.com India

Mar 25, 2025

Mar 24, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Stockholders to Connect - Markets Insider

Mar 24, 2025

Mar 24, 2025

How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion - Nasdaq

Mar 24, 2025

Mar 23, 2025

Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Markets Insider

Mar 23, 2025

Mar 23, 2025

Is This Stock a Buy After a Massive 20% Drop in 1 Day? - Yahoo Finance

Mar 23, 2025

Mar 23, 2025

StockWatch: After DMD Patient Death, Analysts Still Bullish on Sarepta - Genetic Engineering & Biotechnology News

Mar 23, 2025

Mar 22, 2025

PNC Financial Services Group Inc. Has $352,000 Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World

Mar 22, 2025

Mar 22, 2025

Scotiabank Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price - Defense World

Mar 22, 2025

Mar 22, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Mar 22, 2025

Mar 21, 2025

Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving Up - NewsBreak: Local News & Alerts

Mar 21, 2025

Mar 21, 2025

Nvidia, Nike, Sarepta Therapeutics, Protalix and more analyst calls of the week - Proactive Investors UK

Mar 21, 2025

Mar 21, 2025

This Is What Whales Are Betting On Sarepta Therapeutics - Benzinga

Mar 21, 2025

Mar 21, 2025

Regenxbio’s Triple Threat: Partnered Programs, DMD Progress And In-House Manufacturing - News & Insights

Mar 21, 2025

Mar 21, 2025

Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Givi - Asianet Newsable

Mar 21, 2025

Mar 21, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 4% After Analyst Downgrade - Defense World

Mar 21, 2025

Mar 21, 2025

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance

Mar 21, 2025

Mar 21, 2025

HC Wainwright Reiterates “Sell” Rating for Sarepta Therapeutics (NASDAQ:SRPT) - Defense World

Mar 21, 2025

Mar 21, 2025

Sarepta Therapeutics Target of Unusually High Options Trading (NASDAQ:SRPT) - Defense World

Mar 21, 2025

Mar 20, 2025

Sarepta plunges after death linked to Elevidys (update) - MSN

Mar 20, 2025

Mar 20, 2025

Sarepta: Should Investors Run For The Exit? (NASDAQ:SRPT) - Seeking Alpha

Mar 20, 2025

Mar 20, 2025

Sarepta Therapeutics’ stock falls after patient dies of liver failure - MSN

Mar 20, 2025

Mar 20, 2025

Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More - Zacks Investment Research

Mar 20, 2025

Mar 20, 2025

Regenxbio Rises After Duchenne Update And Sarepta Safety Scare - News & Insights

Mar 20, 2025

Mar 20, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Investors to Inquire about Securities Investigation - Markets Insider

Mar 20, 2025

Mar 20, 2025

Sarepta Therapeutics stock falls after DMM patient dies of liver failure - MSN

Mar 20, 2025

Mar 20, 2025

Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades - PharmaVoice

Mar 20, 2025

Mar 20, 2025

In Wake of Elevidys Death, Duchenne Patient Community Vows to Push On - BioSpace

Mar 20, 2025

Mar 20, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Given New $99.00 Price Target at Deutsche Bank Aktiengesellschaft - Armenian Reporter

Mar 20, 2025

Mar 20, 2025

Sarepta Therapeutics’ SWOT analysis: strong Elevidys sales offset safety concerns By Investing.com - Investing.com South Africa

Mar 20, 2025

Mar 20, 2025

Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength? - Yahoo Finance

Mar 20, 2025

Mar 20, 2025

Pulse of the Market: Wednesday’s 10 Top Performers - Insider Monkey

Mar 20, 2025

Mar 20, 2025

Medical Stocks To Follow Today – March 18th - Defense World

Mar 20, 2025

Mar 19, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sarepta Therapeutics, Inc. (SRPT) And Encourages Investors to Reach Out - ACCESS Newswire

Mar 19, 2025